Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, 27710, USA.
Duke Cancer Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Cancer Treat Res. 2023;190:273-320. doi: 10.1007/978-3-031-45654-1_9.
Dynamic regulation of the chromatin state by Polycomb Repressive Complex 2 (PRC2) provides an important mean for epigenetic gene control that can profoundly influence normal development and cell lineage specification. PRC2 and PRC2-induced methylation of histone H3 lysine 27 (H3K27) are critically involved in a wide range of DNA-templated processes, which at least include transcriptional repression and gene imprinting, organization of three-dimensional chromatin structure, DNA replication and DNA damage response and repair. PRC2-based genome regulation often goes wrong in diseases, notably cancer. This chapter discusses about different modes-of-action through which PRC2 and EZH2, a catalytic subunit of PRC2, mediate (epi)genomic and transcriptomic regulation. We will also discuss about how alteration or mutation of the PRC2 core or axillary component promotes oncogenesis, how post-translational modification regulates functionality of EZH2 and PRC2, and how PRC2 and other epigenetic pathways crosstalk. Lastly, we will briefly touch on advances in targeting EZH2 and PRC2 dependence as cancer therapeutics.
多梳抑制复合物 2(PRC2)通过动态调节染色质状态,为表观遗传基因调控提供了一种重要的手段,这种调控可以深刻影响正常发育和细胞谱系特化。PRC2 及其诱导的组蛋白 H3 赖氨酸 27(H3K27)甲基化,在多种 DNA 模板过程中起着关键作用,这些过程至少包括转录抑制和基因印记、三维染色质结构的组织、DNA 复制以及 DNA 损伤反应和修复。基于 PRC2 的基因组调控在疾病中经常出错,尤其是癌症。本章讨论了 PRC2 及其催化亚基 EZH2 介导(表观)基因组和转录组调控的不同作用模式。我们还将讨论 PRC2 核心或辅助成分的改变或突变如何促进致癌作用,翻译后修饰如何调节 EZH2 和 PRC2 的功能,以及 PRC2 和其他表观遗传途径如何相互作用。最后,我们将简要介绍靶向 EZH2 和 PRC2 依赖性作为癌症治疗的进展。